Inflammatory Bowel Disease in Adults and Elderly: The Use of Selected Non-IBD Medication Examined in a Nationwide Cohort Study

被引:0
作者
Lund, Ken [1 ,2 ,8 ]
Zegers, Floor Dijkstra [1 ]
Nielsen, Jan [1 ,2 ]
Brodersen, Jacob Broder [3 ,4 ]
Knudsen, Torben [3 ,4 ]
Kjeldsen, Jens [5 ,6 ]
Larsen, Michael Due [1 ,7 ]
Norgard, Bente Mertz [1 ,2 ]
机构
[1] Odense Univ Hosp, Ctr Clin Epidemiol, Odense, Denmark
[2] Univ Southern Denmark, Dept Clin Res, Res Unit Clin Epidemiol, Odense, Denmark
[3] Hosp Southwest Jutland, Dept Med Gastroenterol, Esbjerg, Denmark
[4] Univ Southern Denmark, Dept Reg Hlth Sci, Esbjerg, Denmark
[5] Odense Univ Hosp, Dept Med Gastroenterol S, Odense, Denmark
[6] Univ Southern Denmark, Dept Clin Res, Res Unit Med Gastroenterol, Odense, Denmark
[7] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway
[8] Univ Southern Denmark, Odense Univ Hosp, Ctr Clin Epidemiol, Dept Clin Res,Res Unit Clin Epidemiol, Kloevervaenget 30,Entrance 216, DK-5000 Odense, Denmark
关键词
inflammatory bowel disease; Crohn's disease; ulcerative colitis; non-IBD medication; adult; elderly; PROTON PUMP INHIBITOR; RISK; EPIDEMIOLOGY; DEPRESSION; QUALITY;
D O I
10.1093/ibd/izad244
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Real-world data on medications used for conditions other than inflammatory bowel disease (IBD) are sparse. We examined how the onset of IBD affects the prescription pattern of selected non-IBD medication and the risk of becoming an incident user.Methods This nationwide cohort study utilized data from Danish health registers. We included incident patients with young adult-onset IBD (18-39 years of age), adult-onset IBD (40-59 years of age), and elderly-onset IBD (60+ years of age), from 1998 to 2018 and followed all for 3 years. We examined redeemed prescriptions before and after the onset of IBD and estimated the risk of becoming a user of non-IBD medications using logistic regression models.Results We identified 36165 patients, 16 771 (46%) with young adult onset, 10615 (29%) with adult onset, and 8779 (24%) with elderly onset. The onset of IBD increased the use of antidepressants, antipsychotics, sedatives/hypnotics, opioids, nonopioid analgesics, antidiabetics, and proton pump inhibitors, even in patients with no other underlying comorbid diseases. The adjusted odds ratio for using antidepressants 1 year after the onset of IBD in elderly was 1.50 (95% confidence interval [CI], 1.14-1.82), in opioids 1.69 (95% CI, 1.45-1.95), in nonopioid analgesics 2.10 (95% CI, 1.77-2.48), in cardiovascular medication 2.20 (95% CI, 1.86-2.61), and in proton pump inhibitors 1.51 (95% CI, 1.31-1.74) compared with adults.Conclusions In all 3 age groups, the proportions of patients with redeemed prescriptions for several groups of non-IBD medication were significantly increased after the IBD diagnosis compared with before. The risk of becoming an incident user for several groups of non-IBD medication was increased in elderly patients. In patients with young adult onset, adult onset, and elderly onset of inflammatory bowel disease (IBD), the proportions of prescriptions for non-IBD medication was significantly increased after the IBD onset compared with before. The risk of new use of non-IBD medication was increased in elderly-onset IBD patients. Graphical Abstract
引用
收藏
页码:1965 / 1973
页数:9
相关论文
共 34 条
  • [21] Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids
    Noureldin, Mohamed
    Higgins, Peter D. R.
    Govani, Shail M.
    Cohen-Mekelburg, Shirley
    Kenney, Brooke C.
    Stidham, Ryan W.
    Waljee, Jennifer F.
    Waljee, Akbar K.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (01) : 74 - 83
  • [22] The Danish Civil Registration System
    Pedersen, Carsten Bocker
    [J]. SCANDINAVIAN JOURNAL OF PUBLIC HEALTH, 2011, 39 : 22 - 25
  • [23] Data Resource Profile: The Danish National Prescription Registry
    Pottegard, Anton
    Schmidt, Sigrun Alba Johannesdottir
    Wallach-Kildemoes, Helle
    Sorensen, Henrik Toft
    Hallas, Jesper
    Schmidt, Morten
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2017, 46 (03) : 798 - +
  • [24] Disparities Persist in Inclusion of Female, Pregnant, Lactating, and Older Individuals in Inflammatory Bowel Disease Clinical Trials
    Rabinowitz, Loren G.
    Rabinowitz, Danielle G.
    Silver, Emily M.
    Oxentenko, Amy S.
    Williams, Kevin E.
    Silver, Julie K.
    [J]. GASTROENTEROLOGY, 2022, 163 (01) : 8 - 13
  • [25] Rodriguez-Lago Iago, 2022, Gastroenterol Hepatol, V45, P457, DOI 10.1016/j.gastrohep.2021.07.009
  • [26] Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study
    Rungoe, Christine
    Basit, Saima
    Ranthe, Mattis Flyvholm
    Wohlfahrt, Jan
    Langholz, Ebbe
    Jess, Tine
    [J]. GUT, 2013, 62 (05) : 689 - 694
  • [27] The Danish National Patient Registry: a review of content, data quality, and research potential
    Schmidt, Morten
    Schmidt, Sigrun Alba Johannesdottir
    Sandegaard, Jakob Lynge
    Ehrenstein, Vera
    Pedersen, Lars
    Sorensen, Henrik Toft
    [J]. CLINICAL EPIDEMIOLOGY, 2015, 7 : 449 - 489
  • [28] The Danish Civil Registration System as a tool in epidemiology
    Schmidt, Morten
    Pedersen, Lars
    Sorensen, Henrik Toft
    [J]. EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2014, 29 (08) : 541 - 549
  • [29] Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
    Silverberg, Mark S.
    Satsangi, Jack
    Ahmad, Tariq
    Arnott, Ian D. R.
    Bernstein, Charles N.
    Brant, Steven R.
    Caprilli, Renzo
    Colombel, Jean-Frederic
    Gasche, Christoph
    Geboes, Karel
    Jewell, Derek P.
    Karban, Amir
    Loftus, Edward V., Jr.
    Pena, A. Salvador
    Riddell, Robert H.
    Sachar, David B.
    Schreiber, Stefan
    Steinhart, A. Hillary
    Targan, Stephan R.
    Vermeire, Severine
    Warren, Bryan F.
    [J]. CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 19 : 5A - 36A
  • [30] Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases
    Singh, Siddharth
    Iversen, Aske T.
    Allin, Kristine H.
    Jess, Tine
    [J]. JAMA NETWORK OPEN, 2022, 5 (09) : E2234200